Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 4, Issue 3, Pages 201-207Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2008.04.004
Keywords
Nanoconjugates; Magnetic resonance imaging; Subcellular targeting
Funding
- National Institutes of Health [CA107467, EB002100, P50 CA89018, U54CA119341]
- Department of Energy (DOE) [FG02-04 ER 63920]
- Siemens Medical Solutions
- Office of Science, Office of Basic Energy Sciences [W-31-109-Eng-38]
Ask authors/readers for more resources
Nanoconjugates composed of titanium dioxide (TiO2) nanoparticles, DNA oligonucleotides, and a gadolinium (Gd) contrast agent were synthesized for use in magnetic resonance imaging. Transfection of cultured cancer cells with these nanoconjugates showed them to be superior to the free contrast agent of the same formulation with regard to intracellular accumulation, retention, and subcellular localization. Our results have shown that 48 hours after treatment, the concentration of Gd in nanoconjugate-treated cells was 1000-fold higher than in cells treated with contrast agent alone. Consequently, T1-weighted contrast enhancements were observed in cells treated with nanoconjugates but not in cells treated by the contrast agent alone. This type of nanoconjugate with increased retention time, Gd accumulation, and intracellular delivery may find its use in Gd neutron-capture cancer therapy. (C) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available